Dear Sirs,

The coronavirus disease 2019 (COVID-19) pandemic has spread rapidly all around the world. Between March 5th and April 12th, 2020, more than 1200 patients with a positive reverse transcriptase PCR for SARS-CoV-2 were admitted to our secondary hospital. Eight of them had concurrent ischemic stroke during the viral disease. Here, we describe the clinical and imaging features, and outcome, of these patients.

Stroke occurred, while in hospital in six patients and at home in the other two patients. All of them met the diagnostic criteria for severe COVID-19 as previously defined \[[@CR1]\]. Detailed description of cases is provided in the Supplementary Material (Online Resources 1, 2). One was a woman and seven (88%) were men, with a median age of 68.5 years (Table [1](#Tab1){ref-type="table"}). None of them had had a previous stroke. Hypertension was the most common vascular risk factor (63%). Four patients were on antithrombotic therapy prior to admission: three patients were on antiplatelets (one as a secondary prevention after myocardial infarction, and two as a primary prevention due to a high vascular risk); and one on acenocoumarol due to atrial fibrillation. All the patients who suffered in-hospital strokes were on standard thromboprophylaxis with enoxaparine since admission except for the patient with atrial fibrillation, who was on subcutaneous enoxaparine 60 mg bid. Ischemic stroke occurred a median of 11.5 days after the onset of COVID-19 symptoms (interquartile range, IQR 2.8--16.3). Among hospitalized patients, stroke occurred a median of 5.5 days after admission (IQR 3.5--7.5). Bilateral lung infiltrates on chest X-ray were present in all. At the time of stroke, turbidimetric D dimer was \>2,000 µg/l in 63% (5/8) of patients (median 2,515 µg/l; IQR 985--15,500; normal value \<500 µg/l). Antiphospholipid antibodies were not obtained.Table 1Characteristics of eight patients with COVID-19 and ischemic strokeDemographicsFemale gender, no. (%)1 (12)Age (years), median (IQR)68.5 (59--77.3)Basal mRS, median (IQR)0 (0--2.5)Hypertension, no. (%)5 (63)Diabetes, no. (%)3 (38)Dyslipidemia, no. (%)4 (50)BMI (kg/m^2^), median (IQR)27.2 (24.9--29.1)Smoking, no. (%)0 (0)Previous stroke, no. (%)0 (0)Coronary heart disease, no. (%)1 (13)Atrial fibrillation, no. (%)1 (13)Previous antithrombotic therapy Antiplatelet, no. (%)3 (38) Anticoagulant, no. (%)1 (13)Treatments Oxygen therapy  Oxygen supplementation, no. (%)4 (50)  NIMV, no. (%)1 (13)  IMV, no. (%)3 (38) ICU admission, no. (%)3 (38) Hydroxychloroquine, no. (%)7 (88) Azithromycin, no. (%)7 (88) Corticoids, no. (%)6 (75) Tocilizumab, no. (%)5 (63) Previous thromboprophylaxis, no. (%)6 (75)Stroke presentation Time from COVID-19 onset to stroke (days), median (IQR)11.5 (2.8--16.3) Time from admission to stroke (days), median (IQR)5.5 (3.5--7.5)Stroke place At home, no. (%)2 (25) In-hospital, no. (%)6 (75)NIHSS score, median (IQR)27 (15.8--39.3)D dimer (turbidimetric) (µg/l), median (IQR)2,515 (985--15,500)No. of cerebral arterial territories involved 1, no. (%)5 (63) \>1, no. (%)3 (37)Arterial territories involved ACA, no. (%)0 (0) MCA, no. (%)5 (63) PCA, no. (%)3 (37) BA, no. (%)3 (37)Thrombus on CT angiogram (*n* = 4), no. (%)3 (75)Outcome (mRS) ≤ 2, no. (%)2 (25) 3--5, no. (%)2 (25) 6, no. (%)4 (50)*ACA* anterior cerebral artery, *BA*basilar artery, *BMI*body mass index, *ICU*intensive care unit, *IQR*interquartile range, *IVM*invasive mechanical ventilation, *MCA*middle cerebral artery, *mRS*modified Rankin scale, *NIHSS*National Institute of Health stroke scale, *NIVM*non-invasive mechanical ventilation, *PCA*posterior cerebral artery

Overall, five strokes involved one cerebral arterial territory and three involved two or more arterial territories. All of them were large artery infarctions as diagnosed by clinical and cranial CT findings (four anterior circulation infarctions, three posterior circulation infarctions, and one with both anterior and posterior circulation infarctions). Magnetic resonance imaging was not performed on any patient. Only one patient met definite TOAST criteria for the diagnosis of large artery atherosclerotic infarction, and another one had a probably cardioembolic stroke due to preexisting atrial fibrillation (incomplete evaluation) \[[@CR2]\]. None of the other six patients met diagnostic criteria for atherosclerotic, cardioembolic, or small vessel ischemic stroke (three with cryptogenic strokes, and three with incomplete evaluation). Intraarterial thrombi with absence of significant atherosclerotic plaques were observed in the intracranial or supra-aortic arteries in three out of four patients in which CT angiograms were obtained. Four patients did not undergo CT angiography due to a worsening in their respiratory and neurological performance despite therapy. Limitation of the therapeutic effort was applied in these cases, and patients died early after the stroke diagnosis without additional diagnostic workup. Two patients had other thrombotic disorders (one with a pulmonary embolism, patient no. 8 in Supplementary table; and another one with a floating aortic arch thrombus, patient no. 3).

None of the patients met criteria for receiving reperfusion therapies of the occluded arteries. Two of them were started on acetylsalicylic acid, and four received subcutaneous enoxaparine 1 mg/kg bid. On evolution, four patients (50%) died, one remains in a minimally conscious state, one has a severe focal neurological deficit (left middle cerebral artery syndrome), and two have moderate focal neurological deficits, after a median follow-up of 29 days for survivors.

In this series of eight patients, although the evidence is limited by its observational nature and sample size, severe COVID-19 was associated with non-atherosclerotic, large artery ischemic strokes. A high frequency of vertebrobasilar territory involvement was noted, and most patients did not meet diagnostic criteria for common causes of ischemic stroke \[[@CR3]\]. Observed cumulative incidence of ischemic stroke during the period included in this series largely exceeds the expected incidence for our 1,200 admitted subjects during the 39 days evaluated \[[@CR4]\].

At this point, in the growing knowledge about the mechanisms underlying the high morbidity and mortality associated to COVID-19, an atypical and enhanced form of acute coagulopathy secondary to endothelial disfunction and an inflammation-mediated prothrombotic state seem to be playing an important role. In the context of severe disease, vascular wall inflammation can initiate thrombus formation by activating endothelial cells, platelets, and leukocytes, which would trigger the coagulation pathway \[[@CR5]--[@CR7]\]. This may induce a prothrombotic state that confers a high risk for ischemic stroke, either by a direct damage to a previously healthy endothelial wall or by enhancing a thrombotic effect in cases where a specific cause, such as atherosclerosis, is present \[[@CR8], [@CR9]\]. If larger prospective studies confirm these observations, hypercoagulability associated with COVID-19 might be a contributory cause for large vessel ischemic stroke. Until robust evidence is available, the observation of intraarterial thrombi in the absence of significant atherosclerosis among these patients warrants consideration of individualized enhanced thromboprophylaxis for hospitalized patients with severe forms of SARS-CoV-2 infection.
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